Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
Cerilliant
Argus Health
UBS
Chinese Patent Office
QuintilesIMS
Chubb
Johnson and Johnson
Julphar
Fish and Richardson

Generated: October 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,056,886

« Back to Dashboard

Which drugs does patent 7,056,886 protect, and when does it expire?


Patent 7,056,886 protects GATTEX KIT and is included in one NDA.

This patent has sixteen patent family members in twelve countries.

Summary for Patent: 7,056,886

Title:GLP-2 formulations
Abstract: The invention is directed to formulations of GLP-2 peptides and analogs thereof exhibiting superior stability following storage and/or exposure to elevated temperatures. The GLP-2 compositions comprise a GLP-2 peptide or an analog thereof, a phosphate buffer, L-histidine, and mannitol.
Inventor(s): Isaacs; Indu J. (Andover, MA)
Assignee: NPS Allelix, Corp. (Mississauga, CA)
Application Number:09/750,022
Patent Claim Types:
see list of patent claims
Formulation; Process; Use; Device;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Nps Pharms Inc
GATTEX KIT
teduglutide recombinant
POWDER;SUBCUTANEOUS203441-001Dec 21, 2012RXYesYes► Subscribe► SubscribeY TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME WHO ARE DEPENDENT ON PARENTERAL SUPPORT
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,056,886

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9930882Dec 30, 1999

International Patent Family for Patent: 7,056,886

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria353665► Subscribe
Australia2462601► Subscribe
Australia782110► Subscribe
Canada2395814► Subscribe
Germany60033437► Subscribe
Denmark1246639► Subscribe
European Patent Office1246639► Subscribe
Spain2282161► Subscribe
United Kingdom9930882► Subscribe
Hong Kong1050142► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

McKesson
Novartis
Federal Trade Commission
Healthtrust
Express Scripts
Merck
Argus Health
Cipla
Covington
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot